mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Company profile
Ticker
MIRM
Exchange
Website
CEO
Christopher Peetz
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Mirum Pharmaceuticals AG, a company • Mirum Pharmaceuticals International B.V., a company ...
IRS number
831281555
MIRM stock data
Latest filings (excl ownership)
8-K
Other Events
17 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 24
8-K
Other Events
31 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
8 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
Transcripts
MIRM
Earnings call transcript
2024 Q1
8 May 24
MIRM
Earnings call transcript
2023 Q4
28 Feb 24
MIRM
Earnings call transcript
2023 Q3
2 Nov 23
MIRM
Earnings call transcript
2023 Q2
3 Aug 23
MIRM
Earnings call transcript
2023 Q2
3 Aug 23
MIRM
Earnings call transcript
2023 Q1
6 May 23
MIRM
Earnings call transcript
2023 Q1
4 May 23
MIRM
Earnings call transcript
2022 Q4
8 Mar 23
MIRM
Earnings call transcript
2022 Q3
9 Nov 22
MIRM
Earnings call transcript
2022 Q2
7 Aug 22
Latest ownership filings
4
Christopher Peetz
24 Jul 24
SC 13G
JANUS HENDERSON GROUP PLC
10 Jul 24
4
Jolanda Howe
3 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
4
Pamela Vig
25 Jun 24
144
Notice of proposed sale of securities
24 Jun 24
4
MICHAEL G GREY
7 Jun 24
4
Timothy P Walbert
7 Jun 24
4
Lon Cardon
7 Jun 24
4
Laura Brege
7 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 171 |
Opened positions | 70 |
Closed positions | 27 |
Increased positions | 48 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 1.27 tn |
Total shares | 64.99 mm |
Total puts | 59.70 k |
Total calls | 85.00 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Management | 6.50 mm | $163.16 bn |
Biotechnology Value Fund L P | 4.37 mm | $125.94 mm |
BVF | 4.37 mm | $109.78 bn |
Frazier Life Sciences IX | 3.57 mm | $94.27 mm |
Eventide Asset Managment | 3.30 mm | $82.91 bn |
STT State Street | 2.82 mm | $70.90 bn |
JHG Janus Henderson | 2.77 mm | $69.47 bn |
BLK Blackrock | 2.45 mm | $61.60 bn |
Cadian Capital Management | 2.29 mm | $57.59 bn |
Vanguard | 2.21 mm | $55.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jul 24 | Christopher Peetz | Common Stock | Option exercise | Acquire M | No | No | 2.936 | 34,013 | 99.86 k | 126,783 |
23 Jul 24 | Christopher Peetz | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.936 | 34,013 | 99.86 k | 278,487 |
2 Jul 24 | Jolanda Howe | Common Stock | Sell | Dispose S | No | No | 34 | 375 | 12.75 k | 2,426 |
1 Jul 24 | Jolanda Howe | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,042 | 0.00 | 2,801 |
1 Jul 24 | Jolanda Howe | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,042 | 0.00 | 1,041 |
24 Jun 24 | Pamela Vig | Common Stock | Sell | Dispose S | No | Yes | 34 | 30,559 | 1.04 mm | 27,406 |
24 Jun 24 | Pamela Vig | Common Stock | Option exercise | Acquire M | No | No | 2.936 | 30,559 | 89.72 k | 57,965 |
24 Jun 24 | Pamela Vig | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.936 | 30,559 | 89.72 k | 125,691 |
5 Jun 24 | William Fairey | RSU Common Stock | Grant | Acquire A | No | No | 0 | 5,703 | 0.00 | 5,703 |
5 Jun 24 | William Fairey | Stock Option Common Stock | Grant | Acquire A | No | No | 26.3 | 8,779 | 230.89 k | 8,779 |
News
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
26 Jul 24
Mirum's LIVMARLI Now Approved For Progressive Familial Intrahepatic Cholestasis In Patients 12 Months and Older
25 Jul 24
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
8 Jul 24
Mirum Pharmaceuticals' LIVMARLI Approved In The EU For Patients With PFIC In Patients 3-Months Of Age And Older
8 Jul 24
Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $66
20 Jun 24
Press releases
Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
25 Jul 24
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 24
Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC
8 Jul 24
Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
17 Jun 24
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
16 Jun 24